SynthesisFrontiers in immunology2026
Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of cadonilimab in patients with solid tumors. Methods: We systematically searched seven databases-PubMed, Embase, Web of Science, Cochrane Library, Ovid MEDLINE, Scopus, and ProQuest-for clinical studies published up to July 19, 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) and single-arm trials. Data collected included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) incidence. A meta-analysis of relevant data was performed using a random-effects model. Results: This study encompassed a total of 13 investigations, comprising 11 single-arm clinical trials, and 2 randomized controlled trials. A total of 1,359 patients with solid tumors, including gastric cancer or adenocarcinoma of the gastroesophageal junction and cervical non-small cell lung cancer, were enrolled in the study. The pooled efficacy analysis demonstrated an ORR of 0.45 (95% CI: 0.31-0.59), a DCR of 0.84 (95% CI: 0.71-0.94), a median PFS of 7.47 months (95% CI: 4.98-9.97), and a median OS of 12.89 months (95% CI: 10.09-15.68). Subgroup analysis indicated the highest ORR in cervical cancer (0.63, 95% CI: 0.33-0.94), while the highest DCR was observed in gastric or gastroesophageal junction adenocarcinoma (0.91, 95% CI: 0.82-1.00). The administration of cadonilimab at a dosage of 10 mg/kg every three weeks resulted in the optimal ORR and DCR of 0.71 (95% CI: 0.63-0.80) and 0.95 (95% CI: 0.90-0.99), respectively. A comparison of cadonilimab plus chemotherapy with monotherapy or combination therapy with targeted agents revealed that the former demonstrated superior efficacy, with an ORR and DCR of 0.62 (95% CI: 0.56-0.69) and 0.94 (95% CI: 0.88-1.00), respectively. With respect to safety, the incidence rate of adverse events of any grade was 0.99 (95% CI: 0.98-1.00), the incidence of ≥Grade 3 treatment-related adverse events (TRAEs) was 0.49 (95% CI: 0.34-0.63), and the incidence of ≥Grade 3 immune-related adverse events (irAEs) was 0.11 (95% CI: 0.08-0.14). The most prevalent TRAEs included neutrophil count decreased, anemia, and platelet count decreased. Conclusions: Cadonilimab demonstrates a positive response in the treatment of various solid tumors, exhibiting good tolerability. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251103576.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.